Reverse transcription polymerase chain reaction was used to detect an unusual BCR/ABL transcript in a patient who presented with thrombocythaemia and was Philadelphia chromosome positive but weakly reactive to conventional BCR/ABL fusion probes. Sequencing revealed the presence of a 12 bp insert between BCR exon2 (b2) and ABL exon2 (a2). In such cases the use of conventional BCR/ABL probes may lead to false negative results. This is the first report of this transcript. Clinically the patient has responded well to therapy.
Introduction
Both chronic myelogenous leukaemia (CML) and essential thrombocythaemia (ET) are myeloproliferative disorders. Opinions have differed whether the absence of the Philadelphia chromosome (Ph) is required for ET diagnosis. Some 1-3 have studied Ph + ET whereas others discuss CML with thrombocythemic onset. 4, 5 CML is characterized by leukaemic cells bearing the Philadelphia chromosome, a t(9;22)(q34;q11) reciprocal translocation that results in a BCR/ABL fusion gene and a 210 kDa protein product involving the BCR gene of chromosome 22 and the ABL gene of chromosome 9. Exons 12 to 16 of the BCR gene constitute the major breakpoint cluster region with the five exons named b1 to b5. The breakpoint in the ABL gene most commonly occurs before exon 2 and the sequence therefore commences with exon 2 (a2). Some cases of ABL exon a3 fused to BCR exons have been described. 6 The commonest BCR/ABL fusion proteins result from a b2a2 or b3a2 gene fusion and this simplifies the detection of the Philadelphia translocation by genetic technology using a conventional set of gene fusion probes. 7 A patient is reported who presented clinically as essential thrombocythaemia. On the basis of the karyotypic finding of a Philadelphia chromosome she was diagnosed and treated as a CML variant, but with weak hybridization signals using conventional probes, and in whom molecular genetic analysis showed an unusually constituted BCR-ABL rearrangement.
Material and methods

Clinical details
A 35-year-old female patient presented with a moderately raised leukocyte count (25 × 10 9 /l) and markedly raised thrombocytosis (1000 × 10 9 /l), a normal leukocyte alkaline 
Methods
Total RNA was extracted from the patient's bone marrow and peripheral blood cells and control cell lines using the guanidinium thiocyanate method. 8 A combined reverse transcription (RT) and polymerase chain reaction (PCR) method was used 9 followed by a further PCR using a nested primer set. Outer primers were based on published sequences 10, 11 and were: (I) 5′-GAAGTGTTTCAGAAGCTTCTC-3′; (II) 5′-CTGGCCA-CAAATCATACAGTGC-3′. Inner primers and amplification conditions were as described. 7 The number of cycles were 31 and 36, respectively. The RT-PCR-amplified fragments were electrophoresed and visualised with ethidium bromide on a 2% agarose gel. Southern blot hybridisation was performed using digoxigenin-labelled probes (Boehringer Mannheim, Penzberg, Germany) complementary to either the b2a2 or b3a2 junctions of the BCR/ABL fusion gene. 7 The amplicons were sequenced using an ABI 373 sequencer (Applied Biosystems, Foster City, CA, USA).
Results
The RT-PCR-amplified fusion product from the patient was smaller than that expected for a b3a2 gene product but slightly larger than that expected for a b2a2 product (Figure 1a) . Southern blot hybridisation with a b3a2 probe yielded only weak hybridisation in the case of the patient, similar to a control b2a2 case. Strong hybridisation was seen with b3a2 control cases and K562 cell line (Figure 1b ). Higher molecular weight bands seen are possibly ssDNA generated by an excess of primer in the nested reaction. Reprobing with the b2a2 probe produced strong hybridisation only with a control b2a2 case but the patient sample produced no hybridisation and there was a weak signal for the b3a2 control cases (Figure 1c) . The amplicons were sequenced in order to explain both the unexpectedly weak hybridisation results despite the presence of the Ph chromosome and the size difference of the PCR product. Sequencing revealed a b2a2 type junction separated by a 12 bp insert (5′-CTGGATCCATCG-3′). This sequence would produce an in-frame amino acid insert ala-met-asp-pro (AMDP) with the junctional residue changed from lysine to glutamic acid. A 'specific' labelled probe 27 bases in length was made incorporating the 12 bases inserted between the b2a2 junction (5′-AAGGGCTT/CTGGATCCATCG/CTTCCTT-3′) and the gels were reprobed.
The cytogenetic and probe hyridisation data are shown in Table 1 and includes the 'specific' probe analysis of samples from 0 to 44 months. Using the 'specific' probe the patient's PCR products, visualised on ethidium bromide-stained gels, and the hybridisation results now corresponded closely, being strongly positive when the Ph chromosome was present and persisting even when the Ph chromosome was no longer detectable at 31 months. Hybridisation was negative during remission from 33 months onwards.
Discussion
Variant translocations occur in 5% of Ph + CML cases and cytogenetic analysis may be inconclusive in some clinically diagnosed CML cases. Molecular probing using conventional probes is able to detect the chimeric gene transcript in most of these cases.
Atypical BCR-ABL transcripts in CML have been described with the ABL exon a3 fused to BCR exons b3 or b2. 6 The transformation process in CML appears to require a functional BCR/ABL protein so that all insertions and alternative mRNA splicing must preserve the in-frame sequence. 6 The potential exists for the variant proteins to have an altered function with a consequential alteration in phenotype. Whether cases of CML with thrombocythaemia have similar variations of the BCR/ABL fusion sequences remains to be seen. Currently, ET is classified belonging to the BCR/ABL-negative chronic myeloproliferative disorders which include BCR/ABL-negative CML. Our case presented phenotypically as ET but with a BCR/ABL transcript and was classified and treated as CML.
There have been no reports of a consistent correlation of the genotype and phenotype in either CML or ET or the platelet behaviour in CML in general. Several studies 12, 13 showed that CML patients with platelet counts higher than 900 × 10 9 /l had the b3a2 transcript but this was not confirmed. 14 Cervantes et al 4 suggested an association between CML with thrombocythaemic onset and the b3a2 BCR/ABL transcript. A CML patient with thrombocytosis and a BCR exon c3, ABL exon 2 junction and poor response to therapy has been described. 15 However, our case differs in that the transcript was similar to the b2a2 transcript with an inserted sequence, the disease resembling ET due to the marked thrombocytosis, absence of splenomegaly, and normal LAP score. Early reports of ET with a Ph chromosome 1 have not included detailed molecular genetic studies but have indicated that the prognosis in ET was similar to that in CML. A later study 13 noted that the BCR/ABL transcript was not detected in four ET cases who were Ph chromosome negative. A CML case was reported 16 with a coamplified acute lymphocytic leukaemia-type BCR/ABL fusion transcript with a 21 bp insert of ABL intron 1b at the e2-a2 fusion.
However, the source of the inserted sequence in our patient has not been found in a gene databank search, possibly because not all of the human ABL gene has been sequenced 17 or may have arisen due to a mutation in the patient. The inserted sequence has, however, remained unchanged and unique, from diagnosis until remission several years later.
It should be noted that hybridisation is not essential if typical BCR/ABL transcripts are visible but a personalized 'specific' probe may be needed to demonstrate the BCR/ABL fusion that may be present with or without karyotypic changes 18 in all potential phenotypic variants of CML. Furthermore, these probes may be invaluable in determining residual disease and in predicting disease-free survival as has been shown in the monitoring of our patient after bone marrow transplantation. This case represents one of a number of variants described and it is important to take advantage of the more sensitive and specific genetic methods when appropriate.
